Building the Future of Precision Medicine

GNQ integrates genomics, artificial intelligence, and advanced computational science to improve the success and efficiency of drug discovery and development.

Our vision

Redefining clinical benchmarks.

To improve human health by accelerating the world’s transition to precision medicine

Our mission

Science at the speed of thought.

To improve the success of drug discovery and development through Genomics, AI and Quantum Computing

system inefficiencies

The Challenge in Drug Development

“The ability to generate a very good quality technical sequence of the human genome exists. But there is a massive gap between having the data in front of us and knowing what it all means”.

GNQ integrates genomics, artificial intelligence, and advanced computational science to improve the success and efficiency of drug discovery and development.

OUR SOLUTION

The GNQ Approach

Partnering with a Fortune 100 company to advance our genomics-driven AI platform, accelerating drug development and time to market.

THE OPPORTUNITY

Unlocking New Possibilities in Precision Medicine

The platform is designed to significantly reduce development time and costs for new therapeutics, with the potential to save billions annually in research and development for leading life science organizations.

GNQ prioritizes a customer-centric approach by tailoring solutions to meet the specific needs of clients in the life sciences and healthcare industries. Understanding their pain points and offering solutions that address them is key to success.

Being a pioneer in this space allows GNQ to explore platform licensing opportunities. Licensing its proprietary technologies, insights, or platforms to other pharmaceutical companies, research institutions, or startups will create new revenue streams and establish GNQ as a leader in the industry.

GNQ's first-mover advantage positions it to lead in innovative drug discovery methods. This can result in faster and more efficient research and development processes, leading to a competitive edge in bringing new therapies to market.

GNQ's first-mover advantage positions it to lead in innovative drug discovery methods. This can result in faster and more efficient research and development processes, leading to a competitive edge in bringing new therapies to market.

Partnering with key players in the life sciences and healthcare industries can provide access to resources, expertise, and distribution channels. Collaborations can enhance research capabilities, accelerate product development, and broaden the reach of GNQ's innovations.

By establishing itself as a first mover, GNQ will build a strong reputation and credibility in the industry. This leadership position attracts talent, investors, and potential partners interested in being part of a ground- breaking endeavor.

GNQ has a clear long-term vision for its role in the drug discovery and healthcare ecosystem. This includes planning for scalability, sustainability, and adaptation to evolving technologies and market dynamics.

LEADERSHIP

Rehan Huda

Founder, Chairperson, Board of Directors
and Chief Executive Officer

  • Has structured numerous public offerings in Canada & the US as investment banking advisor, founder and board member.
  • Former senior economist with Canadian federal government and a frequent guest speaker at various international finance and economics conferences.
  • Previously CEO of Green Sky Labs, a technology incubation company.

Sudhir Saxena

Chief Technology Officer

  • Big 4 Technology leader (IBM, Accenture…) focused on executing Technology based Go-to-Market strategies in Healthcare & Life Sciences.
  • Experienced in Exponential technologies (AI, Blockchain and IOT), to leverage health data as an asset and scale human centered AI across all healthcare facets.
  • Serial entrepreneur and angel investor, with track record in building & growing technology startups.

Asif Mustafa

Chief Financial Officer

  • Over 20 years of experience in finance, risk management, governance, audit, compliance and technology.
  • Held senior finance, operations and change management roles in big Pharma, Wall Street and Big 4 Consulting. Has also held management roles in corporate development, M&A and FP&A in Fortune 100 companies.
  • Technology product management, development and pre-sales experience for major software platform

Dr. Jerome Schentag

Chief Operating Officer

  • Clinical Pharmacology PK/PD specialist with broad expertise in Anti-infectives, Cardio-metabolic and Immuno-Oncology drug development and regulatory sciences.
  • Inventor holding over 90 patents on biologics, drugs medical devices and drug delivery technologies.
  • Founder of TheraSyn and Synergy Therapeutics, actively developing solutions for tumor diagnosis and treatments

Connect with

GNQ

Explore collaboration opportunities and learn how our platform can support your research and development initiatives.